Regenerative Medicine Market In Japan 2026-2030

Description

The regenerative medicine market in japan is forecasted to grow by USD 4389.4 mn during 2025-2030, accelerating at a CAGR of 18.3% during the forecast period. The report on the regenerative medicine market in japan provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by pioneering regulatory environment accelerating commercialization, comprehensive governmental support and strategic national investment, compelling market demand stemming from demographic imperatives.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2026
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	17.6%
CAGR	18.3%
Incremental Value	$4389.4 mn

Technavio's regenerative medicine market in japan is segmented as below:

By Application

Oncology
Musculoskeletal
Dermatology
Others

By Technology

Cell and tissue-based
Gene therapy

By End-User

Hospitals and clinics
Speciality centers
Government and research institutes

Geography

APAC
- Japan

This study identifies the strategic pivot towards allogeneic and off-the-shelf therapies as one of the prime reasons driving the regenerative medicine market in japan growth during the next few years. Also, integration of automation and advanced bioprocessing to industrialize manufacturing and proliferation of strategic alliances and ecosystem-based development models will lead to sizable demand in the market.

The report on the regenerative medicine market in japan covers the following areas:

Regenerative medicine market in japan sizing
Regenerative medicine market in japan forecast
Regenerative medicine market in japan industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading regenerative medicine market in japan vendors that include AnGes Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Cyfuse Biomedical K.K., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Gilead Sciences Inc., HEALIOS K.K., Japan Tissue Engineering Co. Ltd., JCR Pharmaceticals Co. Ltd., Kyowa Kirin Co. Ltd., Megakaryon Corp., Metcela Inc., Novartis AG, ROHTO Pharmaceutical Co. Ltd., Takara Bio Inc., Takeda Pharmaceutical Ltd., Terumo Corp.. Also, the regenerative medicine market in japan analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR76343

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Country Market Characteristics
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
- Overview on factors of disruption
2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Regenerative Medicine Market in Japan 2020 - 2024
- Historic Market Size - Data Table on Regenerative Medicine Market in Japan 2020 - 2024 ($ million)
5.2 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
5.3 Technology segment analysis 2020 - 2024
- Historic Market Size - Technology Segment 2020 - 2024 ($ million)
5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 The AI impact on Regenerative Medicine Market in Japan

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Application

8.1 Market segments
8.2 Comparison by Application
8.3 Oncology - Market size and forecast 2025-2030
8.4 Musculoskeletal - Market size and forecast 2025-2030
8.5 Dermatology - Market size and forecast 2025-2030
8.6 Others - Market size and forecast 2025-2030
8.7 Market opportunity by Application
- Market opportunity by Application ($ million)

9 Market Segmentation by Technology

9.1 Market segments
9.2 Comparison by Technology
9.3 Cell and tissue-based - Market size and forecast 2025-2030
9.4 Gene therapy - Market size and forecast 2025-2030
9.5 Market opportunity by Technology
- Market opportunity by Technology ($ million)

10 Market Segmentation by End-user

10.1 Market segments
10.2 Comparison by End-user
10.3 Hospitals and clinics - Market size and forecast 2025-2030
10.4 Speciality centers - Market size and forecast 2025-2030
10.5 Government and research institutes - Market size and forecast 2025-2030
10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)

11 Customer Landscape

11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Drivers, Challenges, and Opportunity

12.1 Market drivers
- Pioneering regulatory environment accelerating commercialization
- Comprehensive governmental support and strategic national investment
- Compelling market demand stemming from demographic imperatives
12.2 Market challenges
- Navigating complex reimbursement frameworks and pricing pressures
- Overcoming manufacturing scalability hurdles and high cost of goods
- Addressing uncertainty from long-term safety and efficacy data gaps
12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
12.4 Market opportunities
- Strategic pivot towards allogeneic and off-the-shelf therapies
- Integration of automation and advanced bioprocessing to industrialize manufacturing
- Proliferation of strategic alliances and ecosystem-based development models

13 Competitive Landscape

13.1 Overview
13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
13.3 Landscape disruption
- Overview on factors of disruption
13.4 Industry risks
- Impact of key risks on business

14 Competitive Analysis

14.1 Companies profiled
- Companies covered
14.2 Company ranking index
- Company ranking index
14.3 Market positioning of companies
- Matrix on companies position and classification
14.4 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key offerings
- SWOT
14.5 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
14.6 Cyfuse Biomedical K.K.
- Cyfuse Biomedical K.K. - Overview
- Cyfuse Biomedical K.K. - Product / Service
- Cyfuse Biomedical K.K. - Key offerings
- SWOT
14.7 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
14.8 FUJIFILM Holdings Corp.
- FUJIFILM Holdings Corp. - Overview
- FUJIFILM Holdings Corp. - Business segments
- FUJIFILM Holdings Corp. - Key news
- FUJIFILM Holdings Corp. - Key offerings
- FUJIFILM Holdings Corp. - Segment focus
- SWOT
14.9 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Product / Service
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- SWOT
14.10 JCR Pharmaceticals Co. Ltd.
- JCR Pharmaceticals Co. Ltd. - Overview
- JCR Pharmaceticals Co. Ltd. - Product / Service
- JCR Pharmaceticals Co. Ltd. - Key offerings
- SWOT
14.11 Kyowa Kirin Co. Ltd.
- Kyowa Kirin Co. Ltd. - Overview
- Kyowa Kirin Co. Ltd. - Business segments
- Kyowa Kirin Co. Ltd. - Key offerings
- Kyowa Kirin Co. Ltd. - Segment focus
- SWOT
14.12 Megakaryon Corp.
- Megakaryon Corp. - Overview
- Megakaryon Corp. - Product / Service
- Megakaryon Corp. - Key offerings
- SWOT
14.13 Metcela Inc.
- Metcela Inc. - Overview
- Metcela Inc. - Product / Service
- Metcela Inc. - Key offerings
- SWOT
14.14 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
14.15 ROHTO Pharmaceutical Co. Ltd.
- ROHTO Pharmaceutical Co. Ltd. - Overview
- ROHTO Pharmaceutical Co. Ltd. - Business segments
- ROHTO Pharmaceutical Co. Ltd. - Key offerings
- ROHTO Pharmaceutical Co. Ltd. - Segment focus
- SWOT
14.16 Takara Bio Inc.
- Takara Bio Inc. - Overview
- Takara Bio Inc. - Product / Service
- Takara Bio Inc. - Key offerings
- SWOT
14.17 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Product / Service
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- SWOT
14.18 Terumo Corp.
- Terumo Corp. - Overview
- Terumo Corp. - Business segments
- Terumo Corp. - Key news
- Terumo Corp. - Key offerings
- Terumo Corp. - Segment focus
- SWOT

15 Appendix

15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
15.3 Currency conversion rates for US$
- Currency conversion rates for US$
15.4 Research methodology
- Research methodology
15.5 Data procurement
- Information sources
15.6 Data validation
- Data validation
15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
15.8 Data synthesis
- Data synthesis
15.9 360 degree market analysis
- 360 degree market analysis
15.10 List of abbreviations
- List of abbreviations